NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, Forecast & News

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted its quarterly earnings data on Wednesday, November, 6th. The company reported $0.18 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.31) by $0.49. The business earned $168 million during the quarter, compared to the consensus estimate of $152.47 million. Ionis Pharmaceuticals had a return on equity of 36.31% and a net margin of 52.26%. The company's revenue was up 15.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.03) earnings per share. View Ionis Pharmaceuticals' Earnings History.

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Ionis Pharmaceuticals.

12 Wall Street analysts have issued 12-month price targets for Ionis Pharmaceuticals' stock. Their forecasts range from $48.00 to $120.00. On average, they expect Ionis Pharmaceuticals' share price to reach $76.64 in the next twelve months. This suggests a possible upside of 27.8% from the stock's current price. View Analyst Price Targets for Ionis Pharmaceuticals.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ionis Pharmaceuticals.

News headlines about IONS stock have been trending extremely negative recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a daily sentiment score of -5.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Ionis Pharmaceuticals.

Ionis Pharmaceuticals saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 8,480,000 shares, an increase of 10.1% from the December 31st total of 7,700,000 shares. Based on an average trading volume of 983,700 shares, the short-interest ratio is presently 8.6 days. Approximately 6.6% of the company's shares are short sold. View Ionis Pharmaceuticals' Current Options Chain.

Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), Alibaba Group (BABA), BlackRock (BLK), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Gilead Sciences (GILD), NVIDIA (NVDA), Intercept Pharmaceuticals (ICPT) and Allergan (AGN).

Ionis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Tocqueville Asset Management L.P. (0.29%), California Public Employees Retirement System (0.22%), Scout Investments Inc. (0.18%), Peregrine Capital Management LLC (0.15%), Janney Montgomery Scott LLC (0.03%) and Gateway Investment Advisers LLC (0.03%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Gateway Investment Advisers LLC, IFP Advisors Inc, Janney Montgomery Scott LLC, Raymond James Trust N.A., Arden Trust Co, World Asset Management Inc and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

IONS stock was purchased by a variety of institutional investors in the last quarter, including Scout Investments Inc., Peregrine Capital Management LLC, Campbell & CO Investment Adviser LLC, California Public Employees Retirement System, New England Research & Management Inc., Alpine Global Management LLC, Fulton Breakefield Broenniman LLC and Exchange Traded Concepts LLC. View Insider Buying and Selling for Ionis Pharmaceuticals.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IONS stock can currently be purchased for approximately $59.95.

Ionis Pharmaceuticals has a market capitalization of $8.43 billion and generates $599.67 million in revenue each year. The company earns $273.74 million in net income (profit) each year or $2.96 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe.View Additional Information About Ionis Pharmaceuticals.

The official website for Ionis Pharmaceuticals is http://www.ionispharma.com/.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.